Increased hepatic glucagon sensitivity in totally pancreatectomised patients

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Increased hepatic glucagon sensitivity in totally pancreatectomised patients. / Rix, Iben; Lund, Asger B.; Garvey, Lars F.; Hansen, Carsten P.; Chabanova, Elizaveta; Hartmann, Bolette; Holst, Jens J.; Vilsbøll, Tina; Van Hall, Gerrit; Knop, Filip K.

In: European Journal of Endocrinology, Vol. 190, No. 6, 2024, p. 446-457.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Rix, I, Lund, AB, Garvey, LF, Hansen, CP, Chabanova, E, Hartmann, B, Holst, JJ, Vilsbøll, T, Van Hall, G & Knop, FK 2024, 'Increased hepatic glucagon sensitivity in totally pancreatectomised patients', European Journal of Endocrinology, vol. 190, no. 6, pp. 446-457. https://doi.org/10.1093/ejendo/lvae054

APA

Rix, I., Lund, A. B., Garvey, L. F., Hansen, C. P., Chabanova, E., Hartmann, B., Holst, J. J., Vilsbøll, T., Van Hall, G., & Knop, F. K. (2024). Increased hepatic glucagon sensitivity in totally pancreatectomised patients. European Journal of Endocrinology, 190(6), 446-457. https://doi.org/10.1093/ejendo/lvae054

Vancouver

Rix I, Lund AB, Garvey LF, Hansen CP, Chabanova E, Hartmann B et al. Increased hepatic glucagon sensitivity in totally pancreatectomised patients. European Journal of Endocrinology. 2024;190(6):446-457. https://doi.org/10.1093/ejendo/lvae054

Author

Rix, Iben ; Lund, Asger B. ; Garvey, Lars F. ; Hansen, Carsten P. ; Chabanova, Elizaveta ; Hartmann, Bolette ; Holst, Jens J. ; Vilsbøll, Tina ; Van Hall, Gerrit ; Knop, Filip K. / Increased hepatic glucagon sensitivity in totally pancreatectomised patients. In: European Journal of Endocrinology. 2024 ; Vol. 190, No. 6. pp. 446-457.

Bibtex

@article{65d43c55645b4f3bbacb41cbb85e1aa9,
title = "Increased hepatic glucagon sensitivity in totally pancreatectomised patients",
abstract = "OBJECTIVE: The metabolic phenotype of totally pancreatectomised patients includes hyperaminoacidaemia and predisposition to hypoglycaemia and hepatic lipid accumulation. We aimed to investigate whether the loss of pancreatic glucagon may be responsible for these changes. METHODS: Nine middle-aged, normal-weight totally pancreatectomised patients, nine patients with type 1 diabetes (C-peptide negative), and nine matched controls underwent two separate experimental days, each involving a 150-min intravenous infusion of glucagon (4 ng/kg/min) or placebo (saline) under fasting conditions while any basal insulin treatment was continued. RESULTS: Glucagon infusion increased plasma glucagon to similar high physiological levels in all groups. The infusion increased hepatic glucose production and decreased plasma concentration of most amino acids in all groups, with more pronounced effects in the totally pancreatectomised patients compared with the other groups. Glucagon infusion diminished fatty acid re-esterification and tended to decrease plasma concentrations of fatty acids in the totally pancreatectomised patients but not in the type 1 diabetes patients. CONCLUSION: Totally pancreatectomised patients were characterised by increased sensitivity to exogenous glucagon at the level of hepatic glucose, amino acid, and lipid metabolism, suggesting that the metabolic disturbances characterising these patients may be rooted in perturbed hepatic processes normally controlled by pancreatic glucagon.",
keywords = "glucagon, metabolism, totally pancreatectomy, type 1 diabetes",
author = "Iben Rix and Lund, {Asger B.} and Garvey, {Lars F.} and Hansen, {Carsten P.} and Elizaveta Chabanova and Bolette Hartmann and Holst, {Jens J.} and Tina Vilsb{\o}ll and {Van Hall}, Gerrit and Knop, {Filip K.}",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact ",
year = "2024",
doi = "10.1093/ejendo/lvae054",
language = "English",
volume = "190",
pages = "446--457",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "6",

}

RIS

TY - JOUR

T1 - Increased hepatic glucagon sensitivity in totally pancreatectomised patients

AU - Rix, Iben

AU - Lund, Asger B.

AU - Garvey, Lars F.

AU - Hansen, Carsten P.

AU - Chabanova, Elizaveta

AU - Hartmann, Bolette

AU - Holst, Jens J.

AU - Vilsbøll, Tina

AU - Van Hall, Gerrit

AU - Knop, Filip K.

N1 - Publisher Copyright: © The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact

PY - 2024

Y1 - 2024

N2 - OBJECTIVE: The metabolic phenotype of totally pancreatectomised patients includes hyperaminoacidaemia and predisposition to hypoglycaemia and hepatic lipid accumulation. We aimed to investigate whether the loss of pancreatic glucagon may be responsible for these changes. METHODS: Nine middle-aged, normal-weight totally pancreatectomised patients, nine patients with type 1 diabetes (C-peptide negative), and nine matched controls underwent two separate experimental days, each involving a 150-min intravenous infusion of glucagon (4 ng/kg/min) or placebo (saline) under fasting conditions while any basal insulin treatment was continued. RESULTS: Glucagon infusion increased plasma glucagon to similar high physiological levels in all groups. The infusion increased hepatic glucose production and decreased plasma concentration of most amino acids in all groups, with more pronounced effects in the totally pancreatectomised patients compared with the other groups. Glucagon infusion diminished fatty acid re-esterification and tended to decrease plasma concentrations of fatty acids in the totally pancreatectomised patients but not in the type 1 diabetes patients. CONCLUSION: Totally pancreatectomised patients were characterised by increased sensitivity to exogenous glucagon at the level of hepatic glucose, amino acid, and lipid metabolism, suggesting that the metabolic disturbances characterising these patients may be rooted in perturbed hepatic processes normally controlled by pancreatic glucagon.

AB - OBJECTIVE: The metabolic phenotype of totally pancreatectomised patients includes hyperaminoacidaemia and predisposition to hypoglycaemia and hepatic lipid accumulation. We aimed to investigate whether the loss of pancreatic glucagon may be responsible for these changes. METHODS: Nine middle-aged, normal-weight totally pancreatectomised patients, nine patients with type 1 diabetes (C-peptide negative), and nine matched controls underwent two separate experimental days, each involving a 150-min intravenous infusion of glucagon (4 ng/kg/min) or placebo (saline) under fasting conditions while any basal insulin treatment was continued. RESULTS: Glucagon infusion increased plasma glucagon to similar high physiological levels in all groups. The infusion increased hepatic glucose production and decreased plasma concentration of most amino acids in all groups, with more pronounced effects in the totally pancreatectomised patients compared with the other groups. Glucagon infusion diminished fatty acid re-esterification and tended to decrease plasma concentrations of fatty acids in the totally pancreatectomised patients but not in the type 1 diabetes patients. CONCLUSION: Totally pancreatectomised patients were characterised by increased sensitivity to exogenous glucagon at the level of hepatic glucose, amino acid, and lipid metabolism, suggesting that the metabolic disturbances characterising these patients may be rooted in perturbed hepatic processes normally controlled by pancreatic glucagon.

KW - glucagon

KW - metabolism

KW - totally pancreatectomy

KW - type 1 diabetes

U2 - 10.1093/ejendo/lvae054

DO - 10.1093/ejendo/lvae054

M3 - Journal article

C2 - 38781444

AN - SCOPUS:85195709606

VL - 190

SP - 446

EP - 457

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 6

ER -

ID: 394989720